Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy

被引：0
|
作者：
Franke, Katharina
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2021年 / 59卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1255 / +
页数：2
相关论文
共 50 条
  • [31] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [32] Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
    Zhang, Jie
    Wu, Di
    Zhang, Ziran
    Long, Jieran
    Tian, Guangming
    Wang, Yang
    Ma, Xiangjuan
    Chen, Xiaoling
    Han, Jindi
    Hu, Weiheng
    Dai, Ling
    Nie, Jun
    Fang, Jian
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [33] First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
    Sun, Jong-Mu
    Enzinger, Peter C.
    Adenis, Antoine
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
    Roboubi, Amytis
    Wasielewski, Eric
    Bordier, Soraya
    Turlotte, Amelie
    Pavaut, Geoffrey
    Scherpereel, Arnaud
    Cortot, Alexis
    Gauvain, Clement
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [35] First-line chemotherapy in advanced ovarian cancer
    Colombo, N
    Parma, G
    Caspani, G
    Donesana, P
    Marinetti, E
    Mangioni, C
    TUMORI JOURNAL, 1999, 85 (03): : S23 - S26
  • [36] Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
    Luo, Xianmei
    Cai, Tingting
    Wu, Jinyan
    Li, Xingyu
    Wang, Xiaofan
    Ma, Haiying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] Pembrolizumab in combination with first-line chemotherapy with gemcitabine-cisplatin for advanced biliary tract cancer
    d'Abrigeon, Constance
    Cindy, Neuzillet
    BULLETIN DU CANCER, 2024, 111 (06) : 541 - 542
  • [38] Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
    Lin, Nanlong
    Chen, Shiting
    Zheng, Zhiwei
    Song, Xiaobing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 205 - 213
  • [39] Pembrolizumab in the first-line treatment of advanced head and neck cancer
    de Sousa, Luana Guimaraes
    Ferrarotto, Renata
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1321 - 1331
  • [40] The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy
    Ikeda, Go
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 55 - 65
12345